Bioretec Ltd., a pioneer in absorbable orthopaedic implants, announced the appointment of Sarah van Hellenberg Hubar-Fisher as Chief Executive Officer (CEO) effective immediately. Van Hellenberg Hubar-Fisher has served as Bioretec's interim CEO since May 2025 and as a member of the company's Board of Directors since 2021. An accomplished medtech executive, she steps into the CEO role with the aim of expanding the company's commercial footprint following key regulatory milestones.

As a result of this appointment, van Hellenberg Hubar-Fisher will be stepping down from her positions as a member of the Board of Directors, as Vice Chairperson of the Board, and from her duties on the Board's Audit Committee. The Board of Directors has also elected Antti Vasara as its new Vice Chairman and a member of the Board's Audit Committee.

"Sarah brings extensive commercial and management experience in healthcare, including the successful global introduction of new technologies. Her leadership was clearly demonstrated during her time as interim CEO, when she advanced the company's strategic direction," said Kustaa Poutiainen, Chairperson of the Board of Directors of Bioretec. "We look forward to Sarah leading Bioretec towards our goal of becoming a global market leader in breakthrough absorbable orthopaedic implants."

"I am excited to lead Bioretec into its next phase of growth as we bring groundbreaking orthopaedic technologies to market," said van Hellenberg Hubar-Fisher. "Our priorities are clear: accelerate the global launch of RemeOs, build on the strong and sustained success of Activa, and ensure both platforms have the resources and processes required for scale. With RemeOs now CE-marked, Activa's continuing market impact, and a robust innovation pipeline, Bioretec is well-positioned to grow its market presence, deliver significant clinical impact, and create long-term value for our shareholders."